AIATELLA

Overview

AIATELLA is a burgeoning medtech startup founded in 2022 in Helsinki, Finland. Co-founded by Jack Parker and Onni Eriksson, the company specializes in AI-powered cardiovascular imaging tools aimed at transforming the landscape of medical diagnostics through automation. AIATELLA recently secured €2 million in funding to advance its technology, which aims to prevent strokes by early detection of cardiovascular abnormalities. The firm operates out of Finland with initiatives to bring its innovative diagnostic technology to international markets.

Recent Developments

June 2025: AIATELLA raised €2 million in seed funding to further its AI-driven cardiovascular imaging solutions. The round was led by Nordic Science Investments, with additional contributions from Specialist VC, Harjavalta Ventures, Business Finland, and other angel investors. This funding will support clinical trials, regulatory certification efforts, and the scaling of its AI technology.
February 2025: The company received an Instrumentarium Grant to support its preventative approaches to cardiovascular disease.
January 2025: AIATELLA’s CEO Jack Parker was featured as one of the 'AI Visionaries 2025' for his work in healthcare technology, particularly in addressing healthcare disparities.
Slush 2024: AIATELLA successfully demonstrated its preventative screening technology at the event, emphasizing early cardiovascular disease detection.

Attribute	Information
Founding Date	2022
Headquarters	Helsinki, Finland
Founders	Jack Parker, Onni Eriksson
Revenue	Not publicly disclosed
Profits	Not publicly disclosed
Key Investors	Nordic Science Investments
Industry	MedTech
Number of Employees	2-10

Early History

Founded in 2022 by biomedical engineer Jack Parker and technical entrepreneur Onni Eriksson, AIATELLA began its journey to revolutionize cardiovascular diagnostics. Parker’s observations of imaging inefficiencies during his tenure in the UK's NHS inspired the initial concept. Participation in a Helsinki hackathon fostered the collaboration with Eriksson, who had relevant entrepreneurship experience. Initially focusing on the aorta's analysis, the company's AI tools were quickly recognized for their speed and accuracy, signaling a shift from traditional diagnostic methods to automated imaging processes.

Company Profile and Achievements

AIATELLA’s innovative solutions leverage AI to automate patient imaging analysis, reducing diagnostic time dramatically—estimates suggest their technology can make imaging analysis up to 100 times faster than traditional methods. Key achievements include:

Automated Image Measurement (AIM) Technology: This flagship AI technology is at the core of AIATELLA’s operations, enabling the detection and quantification of vascular abnormalities at unprecedented speeds.
Clinical Partnerships and Trials: Ongoing trials and partnerships in the UK and Finland aim to expand the reach and application of their AI tools.
Awards and Recognition: The recognition of CEO Jack Parker in the AI Visionaries 2025 list underscores AIATELLA’s pivotal contributions in healthcare innovation.

Current Operations and Market Position

AIATELLA is positioned as a pioneer in AI-driven cardiovascular diagnostics. It focuses on enabling a shift from reactive to preventative healthcare by offering tools that markedly enhance diagnostic speed and efficacy. The company's market position is strengthened by its AI technology's potential to streamline operations in healthcare facilities facing staffing shortages and increasing workloads. AIATELLA is engaged in regulatory processes in the EU and North America and is piloting its technology in hospitals across the UK and the US.

Conclusion

AIATELLA is at the forefront of transforming cardiovascular diagnostics through AI-driven innovations. By automating complex imaging processes, it holds the potential to drastically improve early detection and preventative care in cardiovascular health. With recent investments and strategic partnerships, AIATELLA is poised to extend its impact globally, promising a future where cardiovascular diagnostics are more efficient, equitable, and accessible. As it continues its expansion and regulatory pursuits, AIATELLA is set to redefine the standard of care in cardiovascular medicine.